The thrombopoietin mimetic romiplostim produced a higher rate of platelet response, a lower incidence of treatment failure, less need for splenectomy, and less bleeding than did a variety of standard-of-care therapies in patients with immune thrombocytopenia, according to a report in the Nov. 11 issue of the New England Journal of Medicine. At the same time, romiplostim produced fewer adverse effects than did the traditional treatments, leading to an improved quality of life, wrote Dr. David J. Kuter...